Literature DB >> 20855640

Fixation time does not affect expression of HER2/neu: a pilot study.

Julio A Ibarra1, Lowell W Rogers.   

Abstract

It is said that HER2/neu expression by immunohistochemical analysis varies with the time of fixation. The purpose of this pilot study was to determine the impact of the length of fixation in 10% buffered formalin on the expression of HER2/neu by immunohistochemical analysis. We studied tissue samples from 10 invasive breast cancer cases after fixation for 3, 48, 72, 96, and 120 hours. The tissue was processed immediately after fixation, resembling routine practice. The 50 resulting blocks were then batch stained with PATHWAY HER2/neu clone 4B5 rabbit monoclonal antibody using the Ventana Ultraview DAB detection kit in a Ventana BenchMark XT processor (Ventana, Tucson, AZ). The stained slides were reviewed and scored. We found no significant difference in the intensity of the stain or the percentage of cells stained regardless of the time in fixation. Fixation times between 3 and 120 hours in 10% buffered formalin do not appear to have an impact on the expression of HER2/neu by immunohistochemical analysis.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20855640     DOI： 10.1309/AJCPAIJPSN4A9MJI

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN： 0002-9173            Impact factor:   2.493


  6 in total

1.  HER2 expression in locally advanced gastric cancer with extensive lymph node (bulky N2 or paraaortic) metastasis (JCOG1005-A trial).

Authors:  Tomohiro Matsumoto; Mitsuru Sasako; Junki Mizusawa; Seiichi Hirota; Atsushi Ochiai; Ryoji Kushima; Hitoshi Katai; Yoichi Tanaka; Norimasa Fukushima; Atsushi Nashimoto; Akira Tsuburaya
Journal:  Gastric Cancer       Date:  2014-07-04       Impact factor: 7.370

2.  Evaluation of Formalin Fixation for Tissue Biopsies Using Shear Wave Laser Speckle Imaging System.

Authors:  Saniel D Lim; Qixuan Huang; Eric J Seibel
Journal:  IEEE J Transl Eng Health Med       Date:  2019-04-09       Impact factor: 3.316

3.  fHER2, PR, ER, Ki-67 and Cytokeratin 5/6 Expression in Benign Feline Mammary Lesions.

Authors:  Maria Soares; Assunção N Correia; Mariana R Batista; Jorge Correia; Fernando Ferreira
Journal:  Animals (Basel)       Date:  2022-06-21       Impact factor: 3.231

4.  Formalin fixation on HER-2 and PD-L1 expression in gastric cancer: A pilot analysis using the same surgical specimens with different fixation times.

Authors:  Keita Kai; Yukie Yoda; Atsushi Kawaguchi; Akimichi Minesaki; Hironori Iwasaki; Shinichi Aishima; Hirokazu Noshiro
Journal:  World J Clin Cases       Date:  2019-02-26       Impact factor: 1.337

5.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; David G Hicks; Mitch Dowsett; Lisa M McShane; Kimberly H Allison; Donald C Allred; John M S Bartlett; Michael Bilous; Patrick Fitzgibbons; Wedad Hanna; Robert B Jenkins; Pamela B Mangu; Soonmyung Paik; Edith A Perez; Michael F Press; Patricia A Spears; Gail H Vance; Giuseppe Viale; Daniel F Hayes
Journal:  Arch Pathol Lab Med       Date:  2013-10-07       Impact factor: 5.534

6.  Tumor Content Chart-Assisted HER2/CEP17 Digital PCR Analysis of Gastric Cancer Biopsy Specimens.

Authors:  Keisuke Matsusaka; Shumpei Ishikawa; Atsuhito Nakayama; Tetsuo Ushiku; Aiko Nishimoto; Masayuki Urabe; Nobuyuki Kaneko; Akiko Kunita; Atsushi Kaneda; Hiroyuki Aburatani; Mitsuhiro Fujishiro; Yasuyuki Seto; Masashi Fukayama
Journal:  PLoS One       Date:  2016-04-27       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.